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Abstract
Background
To improve continuity of care at hospital admission and discharge and to decrease medica-
tion errors pharmaceutical care programs are developed. This study aims to determine the
cost-effectiveness of the COACH program in comparison with usual care from a societal
perspective.
Methods
A controlled clinical trial was performed at the Internal Medicine department of a general
teaching hospital. All admitted patients using at least one prescription drug were included.
The COACH program consisted of medication reconciliation, patient counselling at dis-
charge, and communication to healthcare providers in primary care. The primary outcome
was the proportion of patients with an unplanned rehospitalisation within three months after
discharge. Also, the number of quality-adjusted life-years (QALYs) was assessed. Cost
data were collected using cost diaries. Uncertainty surrounding cost differences and incre-
mental cost-effectiveness ratios between the groups was estimated by bootstrapping.
Results
In the COACH program, 168 patients were included and in usual care 151 patients. There
was no significant difference in the proportion of patients with unplanned rehospitalisations
(mean difference 0.17%, 95% CI -8.85;8.51), and in QALYs (mean difference -0.0085, 95%
CI -0.0170;0.0001). Total costs for the COACH program were non-significantly lower than
usual care (-€1160, 95% CI -3168;847). Cost-effectiveness planes showed that the program
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was not cost-effective compared with usual care for unplanned rehospitalisations and
QALYs gained.
Conclusion
The COACH program was not cost-effective in comparison with usual care. Future studies
should focus on high risk patients and include other outcomes (e.g. adverse drug events) as
this may increase the chances of a cost-effective intervention.
Dutch trial register NTR1519
Introduction
Due to the decentralized and fragmented nature of the healthcare delivery system, discontinuity
of care is likely when patients have multiple healthcare providers, none of whom has access to
complete information regarding the patient’s health status [1]. It is therefore not surprising that
medication errors occur most frequently at transitions of care such as hospital admission and
discharge [2–4]. Studies show that up to 95% of patients experience medication errors at hospital
admission, and up to 73% of patients experience medication errors at hospital discharge [4–8].
The causes of these errors are multi-factorial, such as the patient’s inability to accurately recall
his medication use at admission, incomplete transfer of information between healthcare settings
and incorrect transcription of information. Besides medication errors numerous other problems
can occur, e.g. irritation or anxiety of patients, harm to patients due to adverse drug events or
increased costs due to additional healthcare use. Numerous guidelines on medication transfer
have been published to decrease errors and patient harm [9–13]. These guidelines advocate the
implementation of transitional care programs that include medication reconciliation, patient
counselling and communication of medication related information between settings. Although
studies have shown that these transitional pharmaceutical care programs are effective in decreas-
ing medication errors, [4–8] their effects on reducing rehospitalisations are inconsistent [14–21].
In a context of increasing healthcare costs and limited resources, hospitals and professionals
are increasingly concerned about the cost-effectiveness of approaches to improve continuity of
pharmaceutical care [22]. However, only few cost-effectiveness studies in this field have been
performed until now with conflicting results. Previous studies were often model-based eco-
nomic evaluations using multiple assumptions that are debatable [17,23–26]. Moreover, pub-
lished economic evaluations for transitional care programs generally only consider healthcare
costs, exclude the costs of the intervention, use intermediate outcome measures such as medi-
cation errors, lack sensitivity analyses to account for uncertainty around key estimates or
assumptions, and lack an incremental analysis of costs and effects [27,28].
We developed a transitional pharmaceutical care program (COACH, Continuity Of Appro-
priate pharmacotherapy, patient Counselling and information transfer in Healthcare) to
improve the transition of patients from hospital discharge to the community setting [29].
The objective of this study was to evaluate the cost-effectiveness of the COACH program in
patients discharged from the Internal Medicine department in comparison with usual care.
Material and methods
Study design
An economic evaluation alongside a controlled clinical trial with three months follow-up was
performed at a general teaching hospital (OLVG, location West, Amsterdam, The Netherlands).
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OLVG, location West, (former name Sint Lucas Andreas Hospital), is a 550-bed general teach-
ing hospital serving mainly the western part of Amsterdam. This economic evaluation was part
of a larger study focusing on rehospitalisations six months after discharge. As we expected that
patient compliance with filling out cost diaries would decrease over time, patient follow-up for
the economic evaluation was limited to three months.
Usual care patients were included during an eight months period (April 2009-November
2009), see Fig 1. During the next 3.5 months the intervention was implemented (December
2009-March 2010). Intervention patients were included during a nine months period from
March 2010 to December 2010. The study protocol has been described in detail elsewhere
[29].
This study was reviewed by the medical ethical committee and they decided to exempt the
study from review as this is not required for studies that do not affect the patient’s integrity
(according to Dutch legislation). Patient data were obtained and handled in accordance with
privacy regulations. Patients provided written informed consent for gathering data regarding
healthcare use and for filling out cost diaries. The first author (FKC) had access to identifying
patient information.
Study population
All admitted patients at the Internal Medicine department using at least one prescribed drug
for chronic use at hospital admission were invited to participate. Patients could be included in
the study only once. Exclusion criteria were: no informed consent, died during index admis-
sion, transfer to another ward or hospital (as the transitional pharmaceutical care service was
not implemented everywhere), discharge within 24 hours of admission or during out of office
hours, discharge to a nursing home (because patients are not responsible for medication use
themselves) and counselling not possible (as stated by the resident due to physical/mental con-
straints, being critically ill or due to language restrictions without relatives or healthcare per-
sonnel to translate). As we were unable to obtain rehospitalisation data for patients outside the
catchment area of the hospital, these patients were excluded as well.
Fig 1. Usual care and COACH program components and the timeline plus measured outcomes. *discrepancies between
medication prescribed pre-admission and medication prescribed in the hospital. CP = community pharmacy, GP = general
practitioner, PC = patient counselling, MR = medication reconciliation, t = 1,2,3: 1, 2 and 3 months after discharge respectively
https://doi.org/10.1371/journal.pone.0174513.g001
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Usual care
In the usual care condition, no structural medication reconciliation was performed at hospital
admission and discharge, see Fig 1. Residents used the information provided by patients/carers
or previous hospital records to obtain information regarding pre-admission used medication.
Residents and nurses were both involved in instructing patients on how to use their medi-
cation. However, no structured patient counselling was provided at hospital discharge to
explain medication changes. Discharge medication information was communicated to the
general practitioner and community pharmacy. Completeness of information regarding the
pharmacotherapy, including pre-admission prescribed medication, was not checked and little
or no information on (reasons for) changes in the pharmacotherapy was communicated to pri-
mary care providers.
Intervention
The intervention consisted of the COACH program. At hospital admission and discharge,
medication reconciliation was performed by pharmaceutical consultants, supervised by
pharmacists, using a protocol as described previously [29]. Pharmaceutical consultants are spe-
cialised pharmacy technicians who have a three year additional bachelor training in pharma-
ceutical care (e.g. communication with patients, addressing drug-related problems). The
results of the medication reconciliation were discussed with the resident and prescriptions
were adjusted if necessary.
To support patient counselling and communication of discharge information to the next
healthcare provider in the chain, a medication summary for the patient and a discharge over-
view for the community pharmacist and general practitioner were prepared. The medication
summary and discharge overview listed all pharmacotherapy and (reason for) medication
changes. The pharmaceutical consultant counselled the patient and/or the family using the
medication summary to explain the adjustments in the patient’s pharmacotherapy.
The authors of this study were not directly involved in caring for the patients. They were
involved in supervising residents or pharmaceutical consultants in daily routine care.
Study measures
Outcome measures. The primary clinical outcome of this study was the proportion of
patients with at least one unplanned rehospitalisation within three months after discharge. An
unplanned rehospitalisation was defined as an unscheduled hospitalisation to the study hospi-
tal or any of the other five hospitals within the catchment area of the study hospital.
To assess quality of life the EuroQol-5D (EQ-5D) was used [30]. The EQ-5D was included
in the cost diary that was sent to the patient each month. Thus, the EQ-5D was assessed at one,
two and three months after discharge. The EQ-5D measurement at one month was used as
baseline estimate. Utility values for each health state were estimated using the Dutch tariff
[31]. Quality-adjusted life-years (QALYs) were calculated by multiplying the utilities with the
amount of time a participant spent in a particular health state. Transitions between health
states were linearly interpolated [32].
In a post-hoc analysis also the proportion of patients with at least one drug-related rehospi-
talisation within three months after discharge was assessed. A drug-related rehospitalisation
was defined as any admission (scheduled or unscheduled or an emergency department visit)
related to the use of a specific drug. The causality and potential preventability of drug-related
rehospitalisations were assessed by an internal medicine doctor and a hospital pharmacist/
clinical pharmacologist (blinded for study group) as described previously [33].
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Cost measures. Cost data were collected from a societal perspective and categorized into
primary care costs, secondary care costs, medication costs, supportive care costs and lost pro-
ductivity costs (Table 1). Patients received monthly cost-diaries during three months [34–38].
After two postal reminders, three attempts were made to reach patient by telephone to collect
the information.
Primary care costs consisted of costs of contacts with the general practitioner and other pri-
mary healthcare providers such as social workers, and paramedical and complementary thera-
pists. Secondary care costs consisted of hospital admission costs (i.e. hospitalisations, one-day
care and ED-visits), costs for outpatient visits and laboratory tests. Medication costs consisted
of costs for prescription and non-prescription (i.e. over-the-counter) medication [39,40]. Sup-
portive care costs consisted of costs for home care, help from family/friends and help for
housekeeping. Costs due to productivity losses consisted of absenteeism from paid and unpaid
work.
Data on rehospitalisations were gathered using the hospital information systems of the
study hospital and the five other hospitals. Information on prescription medication was
extracted from the hospital’s CPOE (Computerized Physician Order Entry) at discharge and
extrapolated to three months. Medication costs were calculated using Dutch prices [39].
Dutch guideline prices were used to value resource use (Table 1) [41]. When the number of
hours of home care received was unknown, the mean number of hours reported by a leading
Dutch home care organization was used [42]. Paid work absenteeism was valued with Dutch
standard costs using the mean income of the Dutch population according to age and gender. It
was assumed that one working day matched eight productive hours. Unpaid work absenteeism
was valued with Dutch standard costs [41]. If a patient did not report the amount of unpaid
work hours lost, the mean society’s number of hours according to gender was used [43]. All
costs were adjusted to the year 2011. Discounting was not necessary since follow-up was only 3
months.
Intervention costs. A bottom-up calculation was done to determine the costs of the
COACH intervention [44]. For this calculation, the time spent by the pharmaceutical consul-
tant was converted into labour costs. The pharmaceutical consultants needed on average 62.7
minutes (standard deviation: 14.6) per patient. Based on a gross mean year salary of €50.000,
assuming 46 annual working weeks and an efficiency rate of 70%, the labour costs for the inter-
vention were €41.04/patient. We did not include costs of time spent by other healthcare pro-
viders because the extra tasks were performed by the pharmaceutical consultants.
Baseline characteristics. Patient characteristics were extracted from the medical records
of the hospital information system including gender, age, length of stay, and previous hospital
contacts in the six months before inclusion. The Charlson co-morbidity score which has been
shown to be associated with hospitalisations, was used to evaluate the severity of co-morbidi-
ties with higher scores indicating more severe comorbidity [45,46]. Data regarding co-morbid-
ities were obtained from the discharge letter and hospital information system. Validated forms
were used to obtain information on other characteristics from patients themselves, including
information on ethnicity, help with medication use, and marital status.
Data analysis
Included patients were compared on all baseline characteristics using independent T-tests for
continuous variables and chi-square tests for categorical variables.
Analyses were based on group allocation, regardless of whether patients received the com-
plete COACH program, i.e. intention-to-treat analysis. Missing cost and effect data were
imputed separately for the usual care and COACH group using multiple imputation with Fully
Cost-effectiveness of a transitional pharmaceutical care program
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Table 1. Costs used in the economic evaluation, corrected for the year 2011.
Cost (euro)
Intervention costs (per patient)
COACH program 41.04
Primary care: GP (per consult)
GP consultation at practice 28.35
GP home visit 43.53
GP contact by phone / repeat recipe 14.17
GP contact unknown 28.68
Primary care: other (per consult)
Mental health care
Social worker 65.80
Psychologist 80.99
Psychiatrist 104.27
Regional institute for mental welfare 173.11
Paramedical care
Physiotherapist 36.44
Manual therapist 54.67
Clinical nurse specialist 14.44
Dietician 13.67
Complementary care
Complementary therapists Patienta
Secondary care: admission
Hospital admission/day (general hospital) 440.37
Hospital admission/day (academic hospital) 582.09
Intensive care unit/day 2209.93
Emergency department/visit 152.86
One-day hospital care/visit 254.10
Secondary care: other (per consult)
Specialist
Specialist visit at outpatient department 72.89
Specialist contact by phone 36.44
Laboratory test 13.06
Medication (per prescription)
Prescription drugs Dutch pricesb
Non-prescription drugs Patienta
Help received (per hour)
Help for family welfare 24.30
Help from family/friends 12.65
Home carec 35.43
Productivity losses (per hour)
Absenteeism from paid work 23.91–39.61d
Absenteeism from unpaid worke 12.65
a Costs were based on the information provided by the patient
b Medication costs for medication prescribed at discharge were extrapolated for three months using Dutch
prices
c If number of hours was not specified, 22 hours per month was assumed (based on mean use per month as
reported by a leading Dutch homecare organisation)
d Range of costs depending on age and sex
e Absenteeism from household, voluntary work or study/course
GP = General Practitioner
https://doi.org/10.1371/journal.pone.0174513.t001
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Conditional Specification and Predictive Mean Matching in SPSS 21 [40]. A multiple imputa-
tion model was built that included patient’s baseline characteristics that differed between
patients with complete and incomplete follow-up, were associated with an unplanned rehospi-
talisation (p<0.20) or with total costs after three months (p<0.20). Included characteristics
were sex, age, race, marital status, education level, receiving help with medication use, admis-
sion type (planned/unplanned), Charlson co-morbidity score, kidney function, number of
medications at hospital admission and previous hospitalisations in the six months before
inclusion. Five complete data sets were created [40].
Cost and effect differences were estimated using bivariate regression models while adjusting
for confounding variables (p<0.10) [47]. Next, the estimates per data set were pooled using
Rubin’s rules [48].
Both a cost-effectiveness and cost-utility analysis were performed. Incremental cost-effec-
tiveness ratios (ICERs) were calculated by dividing the adjusted difference in mean costs
between the two groups by the adjusted difference in mean outcomes at three months. To
avoid double counting, we excluded the costs of unplanned rehospitalisations in the ICER cal-
culation with unplanned rehospitalisation as effect measure. The uncertainty surrounding the
ICERs was estimated by bootstrapping bivariate regression models including a separate set of
confounders for costs and effects (5000 replications).
The bootstrapped cost effect pairs were represented visually on the cost-effectiveness plane
[49]. The horizontal axis divides the plane according to incremental cost (more expensive
above, less expensive below) and the vertical axis divides the plane according to incremental
effect (more effective on the right, less effective on the left). This divides the incremental cost-
effectiveness plane into four quadrants [50]. The distribution of the cost-effectiveness pairs
over the four quadrants is an indication of the uncertainty around the ICER. Cost-effectiveness
acceptability (CEA) curves were also estimated. In a CEA curve the horizontal axis shows the
threshold (ceiling ratio), which represents the maximum amount of money that a decision
maker is willing to invest to gain 1 unit of effect extra. The vertical axis shows the probability
that the intervention is considered cost-effective in comparison with usual care for a specific
ceiling ratio [51].
Multiple imputation was done using SPSS version 21. The cost-effectiveness analyses were
performed using Stata 12.
Sensitivity analyses
Sensitivity analyses were performed to assess the robustness of the results. In the first analysis,
only complete cases (i.e. patients for which cost diaries for all three months were present) were
included. In the second sensitivity analysis, costs of productivity losses were excluded from the
total costs.
As a sensitivity analysis for the cost-utility analysis, we used a baseline quality of life value at
the moment of discharge (0.39) as reported in a previous study that also included a similar
Internal Medicine patient population [52].
Results
A total of 2274 patients were screened for eligibility for the main study; in total 1486 (65%)
patients were excluded (Fig 2), leaving 788 patients for inclusion in the main study (394
patients COACH program, 394 patients usual care). Of these 788 patients, 469 (60%) were
excluded from the current study mainly because they did not consent to complete monthly
cost diaries, leaving 319 patients for this study (168 patients COACH, 151 patients usual care).
Sixty-five patients (39%) in the COACH program group and 41 patients (27%) in the usual
Cost-effectiveness of a transitional pharmaceutical care program
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care group were lost to follow up. Reasons for dropout were: patient was unreachable, loss of
interest, and feeling too ill to fill out cost diaries.
Patients who participated in the main study, but did not give informed consent for collect-
ing data through cost-diaries for the current study received more often help with their medica-
tion use (31% no consent vs 18% with consent, p<0.01) and were more often non-native
Dutch (38% vs 27%, p<0.01) than patients who did give informed consent. No differences
were found for other baseline characteristics.
Patients included in the COACH group had a higher Charlson co-morbidity score (more
severe co-morbidities) compared to patients in the usual care group (Table 2). Other baseline
patient characteristics did not differ between the two groups.
Fig 2. Flowchart of inclusion of patients.
https://doi.org/10.1371/journal.pone.0174513.g002
Table 2. Patient characteristics for usual care and the COACH program.
Characteristic Usual care (n = 151) COACH (n = 168) p-value
Female, n (%) 71 (47.0) 82 (48.8) 0.75
Age, mean years (SD) 64.5 (15.5) 64.5 (16.5) 0.99
Native Dutch (%) 114 (76.0) 118 (70.2) 0.25
No or low education level (%) 118 (78.1) 129 (77.2) 0.85
Married or having a partner (%) 73 (48.3) 74 (44.0) 0.44
Help with medication use, yes (%) 24 (15.9) 32 (19.0) 0.46
All hospital contacts in the last 6 m*, mean (SD) 0.98 (1.4) 0.95 (1.5) 0.87
Previous hospitalisations in the last 6 m†, mean (SD) 0.60 (1.0) 0.51 (0.9) 0.40
Admission type, planned (%) 40 (26.5) 41 (24.4) 0.67
Length of stay, mean days (SD) 8.4 (6.9) 8.8 (7.2) 0.64
N. of drugs on admission, mean (SD) 6.5 (3.4) 6.7 (3.9) 0.67
Reason for admission (%) 0.87
Renal/urological 23 (15.2) 27 (16.1)
Liver/bile/pancreas 23 (15.2) 22 (13.1)
Infection 30 (19.9) 25 (14.9)
Gastrointestinal 24 (15.9) 27 (16.1)
Diabetes 11 (7.3) 18 (10.7)
Cancer 12 (7.9) 18 (10.7)
Aspecific symptoms 13 (8.6) 14 (8.3)
Other 15 (9.9) 17(10.1)
Kidney function‡ (%) 0.80
Dialysis 9 (6.0) 9 (5.4)
Decreased kidney function 32 (21.2) 43 (25.6)
Unknown 8 (5.3) 7 (4.2)
Total co-morbidities, mean (SD) 3.6 (2.0) 3.7 (2.3) 0.51
Charlson co-morbidity score (%) 0.02
0–1 85 (56.3) 72 (42.9)
2–3 43 (28.5) 49 (29.2)
4–5 16 (10.6) 27(16.1)
>6 7 (4.6) 20 (11.9)
* includes one-day care, ED visits, planned and unplanned admissions in the last 6 months before inclusion
† includes planned and unplanned admissions in the last 6 months before inclusion
‡ kidney function less than 60 ml/min during at least 3 months
https://doi.org/10.1371/journal.pone.0174513.t002
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Of the COACH patients, 157 (93.5%) received medication reconciliation at hospital admis-
sion, all 168 (100%) patients received medication reconciliation at discharge, patient counsel-
ling at discharge and complete information transfer regarding all pharmacotherapy and
medication changes to the community pharmacist. Complete information transfer to the gen-
eral practitioner was achieved for 20 patients (11.9%). Residents failed to upload the updated
discharge information after medication reconciliation into the discharge letter for the general
practitioner or removed information regarding for example discontinued medication. All
steps of the COACH program were implemented in 19 patients (11.3%).
Outcomes and costs
In Table 3, the unadjusted and adjusted pooled outcomes and costs are summarized. The pro-
portion of patients with an unplanned rehospitalisation within three months after discharge
did not significantly differ between groups (21.4% COACH vs 20.5% usual care). There was
also no significant difference in drug-related admissions. Eight patients (4.8%) in the COACH
program and seven patients (4.6%) in the usual care arm had a drug-related admission. Twelve
(80%) of these fifteen drug-related admissions were due to new side effects and, therefore, they
were regarded non-preventable. Three were regarded potentially preventable due to misunder-
standing of a dose increase of metoprolol (usual care), insufficient self-management of a
Table 3. Pooled total effects and costs and differences in total effects and costs during follow-up.
Pooled variables COACH (n = 168) Usual care (n = 151) Difference unadjusted‡ (95% CI) Difference adjusted‡ (95% CI)
Effects
Unplanned rehospitalisation, n (% of pat) 36 (21.4) 31 (20.5) 0.90 (-8.11; 9.90) -0.17 (-8.85; 8.51)
Drug-related rehospitalisation, n (% of
pat)
8 (4.8) 7 (4.6) 0.13 (-4.56; 4.82) -0.90 (-5.56; 3.77)
QALY*, mean 0.15 0.17 -0.0249 (-0.0407; -0.0091) -0.0085 (-0.0170; 0.0001)
Costs, mean
Intervention† 41† 0 41† 41†
Primary care 284 430 -146 (-338; 46) -137 (-325; 51)
GP 101 101 0 (-31; 31) 1 (-29; 31)
Other 183 329 -146 (-338; 46) -138 (-326; 50)
Secondary care 2409 2121 287 (-688; 1262) 251 (-679; 1182)
Admission 2095 1724 371 (-583; 1324) 352 (-563; 1267)
Other 314 397 -83 (-203; 36) -101 (-221; 19)
Medication 448 430 18 (-145; 181) -67 (-219; 86)
Prescription drugs 441 415 26 (-136; 188) -59 (-212; 93)
Non-prescription drugs 7 15 -8 (-17; 1) -7 (-17; 2)
Supportive care 1413 1091 322 (-194; 838) 308 (-230; 846)
Lost productivity 2249 3879 -1630 (-2827; -433) -1558 (-2773; -342)
Total costs 6845 7952 -1107 (-3108; 893) -1160 (-3168; 847)
* The maximum amount of QALY that can be achieved in three months is 0.25 units
† Based on our previous study. The time spent on the medication reconciliation process by the pharmaceutical consultant was converted into labour costs.
‡ The difference between the COACH program costs vs usual care costs. The effect difference for unplanned rehospitalisations was corrected for the
following confounders: Charlson co-morbidity score, help with medication use, number of previous hospitalisations in the last 6 months before inclusion and
number of drugs on admission. The effect difference for drug-related admissions was corrected for Charlson co-morbidity score. The effect difference for
QALY was corrected for: Charlson co-morbidity score, number of drugs on admission, help with medication use and EuroQol value at baseline. The cost
difference was corrected for the following confounders: age, number of previous hospitalisations in the last 6 months before inclusion, help with medication
use, length of hospital stay and Charlson co-morbidity score.
https://doi.org/10.1371/journal.pone.0174513.t003
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hypoglycemia due to insulin masked by metoprolol use and hyponatraemia due to hydrochlo-
rothiazide for a second time (COACH program). Finally, there was no significant difference in
QALYs (0.15 COACH vs 0.17 usual care, Table 3).
Secondary care costs and lost productivity costs together were the greatest contributors to
total costs in both groups (68% for COACH vs 75% for usual care, Table 3). Primary care costs
and lost productivity costs were higher for usual care patients than for patients included in the
COACH program. Secondary care costs and costs for supportive care were higher for the
patients included in the COACH program. However, only the difference in lost productivity
costs was statistically significant (adjusted difference -€1558, 95% CI -2773;-342). Total costs
at three months after discharge did not statistically differ between groups (adjusted difference
-€1160, 95% CI -3168;847).
Cost-effectiveness analyses
The main analysis (Table 4) showed that the incremental cost-effectiveness ratio (ICER) for
decreasing unplanned rehospitalisations was -627,251, indicating lower costs but higher rehos-
pitalisation (mean difference in healthcare costs -€1038, divided by the mean difference in
rehospitalisation 0.0017). As the effect difference is very small, the ICER value becomes very
high. The CE plane showed that the bootstrapped cost-effect pairs were mainly distributed
among the Southeast (47%) and Southwest (41%) quadrant of the CE plane (Fig 3A), confirm-
ing the statistically non-significant differences found in the separate cost and effect analyses.
The acceptability curve (Fig 3B) shows that the COACH program had a probability of being
cost-effective in comparison with usual care ranging from 89% at a willingness to pay no addi-
tional costs to prevent one unplanned rehospitalisation to 68% at a willingness to pay €50,000/
rehospitalisation avoided compared with usual care.
The ICER for drug-related rehospitalisations was -128,804, indicating lower costs but
higher drug-related rehospitalisation (Table 4). The bootstrapped cost-effect pairs were again
distributed among the Southeast (56%) and Southwest (30%) of the CE plane (Fig 4A). The
acceptability curve (Fig 4B) shows that the COACH program had a probability of being cost-
effective in comparison with usual care ranging from 86% at a willingness to pay no additional
costs to 82% at a willingness to pay €50,000 compared with usual care.
Cost-utility analyses
Both the cost and effect differences were not statistically significant. The ICER was 137,059
euro lower per QALY lost in the intervention compared with the control group; or in other
words 137,059 euro per QALY gained in the control group in comparison with the interven-
tion group (Table 4). This large ICER is again caused by the small effect difference.
The cost-effectiveness plane (Fig 5A) shows that 88% of the bootstrapped cost-effect pairs
are situated in the Southwest quadrant, indicating that the intervention is less effective and less
costly than usual care albeit not statistically significantly. The acceptability curve (Fig 5B)
showed a maximum probability of 89% that the COACH program was cost-effective compared
with usual care and decreased with increasing values for willingness to pay per QALY.
Sensitivity analysis
Results of the complete cases analyses also showed no statistically significant differences
between groups regarding unplanned rehospitalisations and drug-related rehospitalisations
(Table 4). In this analysis, the COACH program was also not considered cost-effective in com-
parison with usual care.
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Exclusion of lost productivity costs also showed no statistically significant differences
(Table 4). The acceptability curves for unplanned rehospitalisations and drug-related rehospi-
talisations showed a probability of 16% and 26% respectively that the COACH program was
cost-effective at a willingness to pay no additional costs compared with usual care. The accept-
ability curve for QALY showed similar drops in the probability to be cost-effective compared
to the main analysis.
The results of the sensitivity analysis using a previously reported value for baseline utility
scores showed no difference with the main analysis (Table 4).
Table 4. Results of adjusted cost-effectiveness and cost-utility analyses.
Outcome effect Sample size Adjusted Adjusted Distribution (%) cost-effectiveness plane
COACH Usual
care
cost difference‡
(95% CI)
effect difference§
(95% CI)
ICER¶ North
easta
South
eastb
South
westc
North
westd
Main analyses
Unplanned
rehospitalisation*
168 151 -1038 (-2892; 815) 0.0017 (-0.0855;
0.0888)
-627251 5 47 41 7
Drug-related admission* 168 151 -1153 (-3120; 814) 0.0090 (-0.0545;
0.0724)
-128804 8 56 30 6
QALY 168 151 -1158 (-3158; 842) -0.0085 (-0.0170;
0.0001)
137059 0 1 88 11
Sensitivity analyses
QALYest† in main
analysis
168 151 -1158 (-3161; 845) -0.0085 (-0.0170;
0.0001)
137059 0 1 88 11
Complete cases
Unplanned
rehospitalisation*
80 86 -834 (-2637; 969) -0.0326 (-0.1355;
0.0703)
25592 4 23 59 13
Drug-related admission* 80 86 -550 (-2504; 1404) 0.0020 (-0.0691;
0.0730)
-278455 13 39 33 15
QALY 80 86 -603 (-2618; 1413) -0.0057 (-0.0128;
0.0015)
105951 1 4 70 24
Exclude productivity
losses costs
Unplanned
rehospitalisation*
168 151 516 (-520; 1552) 0.0021 (-0.0854;
0.0895)
251750 43 10 6 41
Drug-related admission* 168 151 405 (-790; 1599) 0.0090 (-0.0544;
0.0723)
45213 47 17 8 27
QALY 168 151 398 (-817; 1614) -0.0085 (-0.0170;
0.0001)
-47053 0 1 25 73
ICER = incremental cost-effectiveness ratio, calculated by difference in costs divided by difference in effect.
* To avoid double counting we excluded the costs of unplanned rehospitalisations or drug-related admissions in the respective cost calculation.
† Baseline quality of life used of a previous study (0.39)
‡ The difference between the COACH program vs usual care for costs. A positive value for cost difference means that the COACH program is more costly
than usual care.
§ The difference between the COACH program vs usual care for QALYs. A positive value for effect difference means that the COACH program is more
effective than usual care. For the rehospitalisation and drug-related admission outcome the effect difference value was multiplied with -1 to keep the cost-
effectiveness plane understandable.
¶ Measures the additional cost per unit of health gain. A negative value indicates that the COACH program is in the northwest or southeast quadrant. A
positive value indicates that the COACH program is in the northeast or southwest quadrant.
a COACH program more effective and more costly than usual care.
b COACH program more effective and less costly than usual care.
c COACH program less effective and less costly than usual care.
d COACH program less effective and more costly than usual care.
https://doi.org/10.1371/journal.pone.0174513.t004
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Discussion
This study showed that there were no statistically significant differences in costs or QALY
effects. Although the cost difference was in favour of the COACH program in the main analy-
sis, the rehospitalisation rate was slightly higher, and confidence intervals were very wide due
Fig 3. Cost-effectiveness analyses for unplanned rehospitalisations. (A) Cost-effectiveness plane for the
risk of unplanned rehospitalisations. (B) Acceptability curve for the cost-effectiveness analyses.
https://doi.org/10.1371/journal.pone.0174513.g003
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to the small sample. In the main analysis, the probability that the COACH program was cost-
effective in comparison with usual care was high (89% for unplanned rehospitalisations). How-
ever, this effect was lost in the sensitivity analyses. The results of the cost-utility analysis
showed lower costs but also lower QALYs in the intervention group. This could also be inter-
preted as higher costs and more QALYs gained in the control group compared with the
Fig 4. Cost-effectiveness analyses for drug-related rehospitalisations. (A) Cost-effectiveness plane for the
risk of drug-related rehospitalisations. (B) Acceptability curve for the cost-effectiveness analyses.
https://doi.org/10.1371/journal.pone.0174513.g004
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intervention group. The ICER of 137,059 is much higher than what would be considered
acceptable by NICE the National Institute for Health Care and Excellence in the UK (which
uses a threshold of 20,000–30,000 British Pounds per QALY gained) or the National Health
Care Institute in The Netherlands (which uses thresholds ranging from 20,000 to 80,000 Euro
Fig 5. Cost-utility analyses. (A) Cost-effectiveness plane for quality adjusted life years. (B) Acceptability curve for
the cost-utility analyses.
https://doi.org/10.1371/journal.pone.0174513.g005
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per QALY gained, depending on the severity of the disease/disorder). Based on these results,
we conclude that the COACH program is not cost-effective in comparison with usual care.
Previous economic evaluations showed variable results [17,23–27]. The study population
and the intervention broadness differed between these studies making comparisons difficult.
Of five evaluations, three studies reported positive results on cost-effectiveness, one study
reported non-significant positive results and one study reported no difference in costs between
groups [17,23–26]. The three positive studies used model-based approaches where the effect of
different types of interventions were based on assumptions in decreasing medication errors
and adverse drug events [23,25,26]. In our economic evaluation we found non-significant dif-
ferences. This was also found in the study of Wallerstedt et al. who reported high ICERs as well
and no effect on rehospitalisations and QALYs (using EQ-5D questionnaires) for Internal
Medicine patients receiving medication review, patient counselling at hospital discharge and a
medication report [24]. There may be several explanations for our findings. First, we included
patients if they used at least one drug. A focus on patients with a higher risk may have been
more effective, such as patients with polypharmacy or patients with multiple hospitalisations
in the history. Two studies showed that a focus on high risk groups was more cost-effective
[24,26]. Second, our program focused on medication reconciliation and not on extensive med-
ication review as opposed to the study of Gillespie et al. and Ghatnekar et al. where positive
results were noted on costs due to drug-related admissions [17,25]. Third, we failed to imple-
ment our study completely, resulting in a low overall intervention fidelity, as general practi-
tioners did not receive the complete medication overview through the discharge letter which
could have influenced results. Finally, our intervention was a pharmaceutical care program. It
is therefore more likely that the intervention could influence unplanned drug-related rehospi-
talisations rather than all cause rehospitalisations. As drug-related rehospitalisations are rare, a
larger sample size was needed to show effects.
We expect that transitional care programs could be cost-effective, but research should
indicate what the effective components are and how the context (including implementation
fidelity) influences the outcomes. For example, in many studies pharmacists are used in transi-
tional care programs, but in the Netherlands this is not feasible due to costs and lack of avail-
ability of pharmacists. Furthermore, transitional care programs prevent medication errors but
the costs of these errors are difficult to clock (e.g. the time needed for rectifying errors, tele-
phone calls to the department, wastage of medication and anxiety experienced by patients).
Also, uncorrected medication errors could lead to adverse drug events [53–55]. Estimates of
costs per adverse drug event range from €900–€1800 [23,56]. In this study, adverse drug events
were not measured.
Strengths of this study are that we collected cost data from a societal perspective and
included rehospitalisation data from multiple hospitals. Limitations of this study also need to
be discussed. First, the existence of selection bias is likely. Only 21% of patients included in the
main study also participated in the economic evaluation. Patients regarded the data collection
as a burden or lacked interest in the study. Patients not participating in the economic evalua-
tion received significantly more frequent help with using medication and were significantly
more frequent non-native Dutch. This limits generalizabilty of the results. Generalizabilty of
the results is also limited due to the monocenter setting of the study. Also, patients included in
the COACH program had more severe co-morbidities than usual care patients. We adjusted
for this, but unknown confounders may be present. Second, complete cost data were available
for only 54% of the patients. Although patients were contacted by telephone to increase
response, this had only a limited effect. Multiple imputation was used to impute missing data
which is currently considered the most appropriate technique to deal with missing data [57–
59]. Baseline data for quality of life at the moment of discharge was not assessed. Therefore,
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the results of the cost-utility analysis should be interpreted with caution. Finally, the follow-up
of three months may have been too short to show an effect on quality of life.
Recommendations for future research include the following. It needs to be assessed
which specific components of transitional care programs are effective. With a stepped wedge
design interventions could be implemented in steps and the effect of these interventions
could be evaluated per (added) step. New studies should evaluate more intensive interventions,
focus on high risk groups and assess multiple outcomes (e.g. adverse drug events). Finally, fol-
low-up should be extended to a period of at least one year as the optimal follow-up period is
unknown.
In conclusion, from a societal perspective, after three months the COACH program was
not considered cost-effective compared to usual care. Future studies are needed to assess
whether and which components are effective for patients transitioning from the hospital set-
ting to the community setting.
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